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INTRODUCTION
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.

Statistical studies have established
the fact that
.
.

15%. of adults in this country have hypertension, and
23.:,& o-f deaths in the age group. past 50 years I!lS-Y be
attributed to that disease.(13}

Analyzed in a aitfer

ent way 500,000 deaths due to cardio-vascular-renal
disease occur annually and 50-75% of these may be
traced to hypertens1on.(2)

These figures reveal that

hypertension is the lead�ng cause of death in pati�nts
past fifty, exceeding even cancer and tuberoulosis.
As the average age of our population has "advanced,
the disease has assumed a more �rom1nent rol.e _-1n mor
tality fi�es.

Thus the treatment of hypertension

has assumed great importarioe in moa,rn therapeutics.
The aim of treatment in this disease is s�111
disputed.

Some clinicians-, considering that llri,e·rten

siori is a.se9ondary manifestation of renal isohemia,
believe �hat increased pressure is bene:ficial 1n a

limited sense and that reduction is contraihdieated.(78)
However, most authorities agree withMoiehtha1(73)
that the "main opject of the treatment of hypertensive·
states is to lower the blood pre�sure and maintain it
at a level w�ieh will not result in the seconda17
changes that are of'ten the cause of death when blood
pressure is pers.istently 'elevated."
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Furt�er analysis of mortality statistics indicates
that the degree of hypertension is directly'corre1ated
with rate of mortality.(2 58 84)

This means that

life expectancy diminishes as blood pressure levels
increase.

Blumenthal and Wetherby(l8) have reported

that even moderate reduction of pressure tends to
prolong life by preventing cerebral hemorrhage, c�diac
failure, and uremia.

An explanation of the beneficial

effect of diminished pressure has been offered by
Corcoran and Page(23) who state that the clinical
improvement is due to decreased arterial pressure

preventing further spread of arteriolar lesions. They

feel that these arteriolar lesions cont�ibute to the

release of reniri,and that limitation of their spread
int�rrupts progress of the disease.
The etiology of hypertension is only partially

understood, and treatment has been in general unsatis
factory.

Recent surgical advances have been encour

aging, and the use of renal antipressor substances
is in a promising experimental state.

However, due

to the present lack of therapeutic specificity,
numerous attempts have been made to employ empirical.
drugs.

The results have been disappointing.

Allen(·l)

has reviewed Beveral drugs u&ed in this attempt and
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points out two factors which have contributed to the
con.fusion in evaluating the results of treatment.
These are (1) the great variability to which blood
pressure is subject and (2) the non-specific e.ffect of
any kind of therapy.
The lability of blood pressure in normal and
hypertensive patients. has long been T'e cognized.

·Early

work by Brown(l9} revealed a daily and_monthly variability of readings in a single hypertensive subject.
Ayman has reported the great fluctuations which occur
in essential hypertension.(6)

Of a group of 76 unse-

lected and untreated cases, more than 50% sho,,1ed occasional levels within norma l range .

And Robinson and

Brucer(87) have· commented again on the marked l ability
o.f pressures in hypertensives in an extensive study
o.f over 11,000 cases.

Allen 8.ttributes the temporary

hypotensive effect of non-specific drugs to psychotherapy in the form of reassurance and enthusiasm
which attend the beginning of new treatment.
It can be seen that the results of ther apy must
be subjected to careful scrutiny to eliminate these·
two sources of error.

One of the few empirical drugs ·

which have proved valuable in reducing pressures
after considering the variables have been the thio-
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cyanates.

Clinical studies accompanied by exacting

controls have established their hypotensive action .
The justification of their use is far less definite ,
the objection being the appearance of toxic manifestations coincident with the therapeutic effect .
The following paper attempts to discuss the
pharmacologic action of the thiocyanates , toxicity,
indicati ons for their use, and to present an unbias ed
evaluation- of their place in the therapeutics of
hypertension .
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HISTORY

The pharmacological action of the thiocyanntes in
·l aborat ory aninals was re ported as early as 1857 by
Claude Bernard . (14)

Therapeutic appl ic ation of these

investigat ions was not attempto.d until the early 1900s
when Pauli(79) announced the results of tre atment of
11 hypertensive patients • . He reported symptomatic
relief and 10- 25% decreas e in blood pressure within
a few days after beginning the drug , followed by a
resumption of the former high levels when therapy w~s
discontinued .

Toxic symptoms in this and subseauent

series were alarm~_ng howe ver , and no particular progress occurred until Westphal in 1926 reported the
results of extensive and apparently successful use
of the thiocyanates in case s of h ypertension . (100)
In the same year Nichols(75) in this country summarized the pharmacolog ical properties of the drug and
announced personal success he had obtained in several
cases .

Following these last two report s , numerous

clinicians began a hopeful trial of the new therapeutic agent .
Severe toxic manifestations soon b e came apparent ,
and with its rejection by the Council on Pharmacy and
Chemistry, the thiocyanates seemed destined for oblivion .
The belated discovery by Barker( l O) of the import ance of

blood levels in effective treatment and control of
untoward symptoms revived interest in the drug .

In

the decade since that discovery the Council has continued to advise against its use, and it has not been
accepted in the N. N.R.

Des pite this fact , re ports of

reputedly successful results have accumulated , and,to
judge by articles in the literature, use of the drug
has by no means decreased within the l•1st fe''! years .
The value of t h iocyanate therapy in hypertension
therefore merits attention .
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PHARMACOLOGY

The thiocyanates occur naturally in the body in
minute quantities and represent the stable and less
toxic form to which the cyanides are converted.

For-

tunately , sulfur does not dissociate from the ion, and
the production of highly poisonous cyanide is avoided .
The thiocyanates have been administered exclusively by the oral route, and absorption thru the intestinal tract is rapid.

The sodium and pot~ssium salts

a r e equally effective and no difference in toxicity
has been established.(3 38)

'

In the body distribu-

tion is similar to that of the chlorides and bromides.(97)

They reach a state of e,...uilibrium in body

fluids within a few hours , do not enter the cells.(25)
An appreciable quantity of thiocyanate , varying from
0.31 to 2.55 -m.grn% can be detected in routine blood
level determinations, and Caviness(22) has attempted
to correlate these levels with blood pressure.
The dru~ remains unchanged in its passage ·thru
the body(25 75) and is excreted mostly by the kidney
and to a lesser extent in the saliva and stools.(64
75 91)

The rate of excretion varies as much as 400%

in the same individual ac~ording to renal function and
fluid balance, which in turn is affected by ph~rs ical
activity , temper--1. ture, and fluid intake.(12)

This
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variation is of great importance and expl a ins fluctuations in blood levels which cannot be accounted for on
the basis of dose administered .
Numerous observers have reported on the experimental toxicity of the thiocyanates.

The me an letha l

doses for various laboratory animals have been determined and the pre-mortal si~ns recorded b y Nichols .(75)
These coincide with signs noted in cases of human
poisoning--apathy , ataxia , dyspnea, convulsions, and
coma.

As in man correlation betv,een blood levels and .

toxic manifestations has been recorded.

Anderson and

Chen(3) summarize their findings stating that "our
results strongly support Barker's advocation that the
safety and toxicity of thiocya.na tes can be measured by
the determination of blood concentration."
Po_st -mortem studies conducted by the above authors
on 6 dogs receiving l ethal doses of the drug failed to
reveal uniform pathol ogical lesions, and adrenal abnormalities were noted in only one of the animals.

Lind-

berg, Wald, and Barker(63) studied necropsy specimens
of 12 dogs to which thiocyanates had been administered
and reported their failure to note adrenal patholo~y
or any increased concentration of the drug in these
glands .

This is of interest since Healy(56) ha s sug-

gested hypoadrenia as the cause -of certain toxic
symptoms in humans.
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In the studies conducted by Lindberg et al., blood
levels of 20 to 60 mgm were established in the dogs.
The observers noted a slow yet striking decrease in
serum protein, erythrocytes, and hemoglobin.

Post-

mortem repor t s in these animals ind icated a relatively
acellular bone marrow resembling that caused by benzol
poisoning and fatty vacuolization of the liver.
Experiments to determine the pharmacodynamic effects of the thiocyanates in laboratory animals will
be described under the section discussing the mode of
action of the drug .
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THERAPEUTICS

.

As has been pointed out, an evaluation of the re-

•

sults of treatment of hypertension is particularly difficult.

Ayman has demonstrated both the extreme

variability in blood pressure in the hypertensive and
the striking symptomatic relief obtained by non-specific therapy .

Therefore careful controls must accompany

the use of a hypotensive agent to validate the conclusions obtained .

Un:f'ortunately, this has not been done

in many of the reports published .
A general survey of the reports published follows . ·
They may be divided into two classes--results obtained
prior to 1936 and those subsequent to this date , in
which blood levels were employed.
The majority of authors(l7 18 36 42 62 65 66 77 78
89 91 100) before 1936 were. impressed by the usefulness
of the drug in a ratio of about 2:1 .

The remainder(5 7

8 35 48 71) were deterred by toxic manifestations , and
one by a fa.ilur·e to note any hypotensi ve effect .
Since 1936 .favorable reports(2 10 11 12 13 15 16
20 21 22 24 28 29 30 31 32 40 51 52 60 61 63 67 68 69
74 81 85 86 90 92 94 96 101) have again been in the
majority, this time by a greater margin than before.
The ratio of favorable to unfavorable articles is

.

roughly 7:1, and one careful observer who reported
negative results in early small series is now con-
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vinced of the therapeutic value of the drug .(68 86)
Those opposed to the use of the thiocyanates(9 27 43
46 54) base their objection on the numerous cases of
toxicity and failure to demonstrate clearly hypotensive effe ct in laboratory animals.
It is interesting to examine the methods of evaluating the results of therapy, and to do this we shall
examine a typ ical re port.

Massie , Ethridge, and O'Hare

in 1938 presented a series of 14 c a ses.

These repre-

sented ambula tory patients fo.llowed at Peter Bent Brigham hospital under various forms of treatment including
sedation for periods of 1 to 17 years.

They were sub-

jected to careful e xamination and case s with serious
renal or ca rdiac dis ease excluded.

Then a test period

of 3 months followed during which no treatment was
g iven and multiple blood pressure readine s were recorded and averaged.
Thiocyanate therapy was then commenced in the
form of a 5% solution in syr up

of

wild cherry.

Blood

leve ls of 5-7fb were established and maintained for a
3-month period.

Following this time thiocyanate medi-

c a tion was withdravm wit;hout the patients' lcnovrl ee;e
and the vehicle alone continued for 3 additional months.
A careful attempt was made to eliminate all psychotherapeutic effects.

No comment concerning expected results
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or progress was all owed , and multiple blood pressure

readings were taken as before .
The results of tre atment in this small series include objective and subjective improvement and the
appearance of toxic manifestations .

Blood pressures

during the 3 months of active treatment were averaged
and indicated decr e a ses in systolic ranging from 21 to
68 mm and in diastolic between 8 and 33 nnn.

With the

cessation of thiocyanates the pressures slowly increased
in every ca se to the original high l evels .

Symptomatic

relief was marked in 12 patients, and it was noted that
a slow return of original complaints paralleled the
rising pressures during the period of placebo administration .

Untoward symptoms occurred in 58% of patients

in this s eries and consisted mainly of a transient feeling of f a tigue .
This report is far from conclusive , but is a t least
indicative of some s pe cific hypotensive effect .

Similar

descriptions of carefully perf ormed studies have furnished confirmatory evidence . (15 40)

Blood pressure

falls of 30 mm or more have been re ported consistently
in 50-75% of the cases tre a ted .

This coincides with the

therapeutic a im expressed by Mosentha l .

The actual ef-

fect on life e xpectancy has not been ana lyzed statis tically , althou gh Kurtz(61) feels that it h a s been
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prolonged, as we should expect from an analysis of
mortality figures.
Practically every observer has noted symptomatic
relief, but the non-specific character of this improvement has been pointed out.

At any rate the thio-

cyanates give as effective relief as do other commonly
used drugs from the usual symptoms of headache, insomnia, nervousness, weakness , anorexia, fatigue, vertigo.
Palmer(35) has reported a large series of cases in
which he obtained striking relief of severe headaches
proved intractable to other forms of therapy, and
some authors have stated that the thiocyanates accomplish subjective relief superior to that noted after
_use of other types of medical treatment.
Dosage-Wide variations in dosage existed among early
workers, and a corresponding confusion in therapeutic
results and toxicity was noted.

It is now realized

that dosage in itself is not important and indeed may
vary widely according to the individual case.

For

initial dosage Goodman and Gilman(49) recommend 0.3 gm
daily for 3 days, followed by b~ood level determ i nation.
They state that maintenance doses vary from 0.3 gm a
week to 1 gm a day, and fluctuations occur f-rom t-ime
to time in the same patient.
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Blood levels-Blood levels of 5-6% should be employed first
and some observers have reported good therapeutic re sults in this range . (24 68)

Barker(l2) states that

l e vels of 8-12 mgm are more often effective and at
the same time not accompanied by serious toxicity .
This is in agreement with the report s of most obs ervers ..

Determinations must be taken a t weekly inter-

vals during the onset of treatment, and this may be
extended to monthly periods later if no untoward
symptoms appear.
Latent period-The latent period of action is about 6 to 10 days
after medica tion is started .

The decr ease in pressure

occurs r a ther slowly re quiring several weeks for maximum effect, and the hypotensive effect of the drug may
be noted for about 2 months after trea tment cease s . (18)
Selection of Cases-Various criteria have been enumer ated for the
selection of ca ses .

It has been noted that much better

results have been obtained in essential hypertension
than in patients with advanced ar ter io sclerotic
changes(ll 17 75 86 91), and studies by Griff ith indicate that lack of capillary mobility decrea_s es effectiveness of treatment . (51)

However , arteriosclero-
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sis represents no definite contraindication to use of

.

the drug, and beneficial effects have been observed
commonly . (18 22 61)

Some observers have noted an in-

crease in toxic symptoms in elderly patients(21 56 74) ,
but careful c~ntrol permits use of the thiocyanates
in this group if no other contraindication exists .
Doles(32) reports that successful results occur
only in patients who have a macrocytic anemia and
limits treatment to cases with this l aboratory finding .

His results have not been corroborated elsewhere .
Cases of malignant hypertension have responded

less well .

If other methods of treatment are inef-

fective , the drug may be employed and some c a ses have
apparently been affected favorably •
Two conditions have been accepted rather generally as contraindications for treatment .

The first

of these is heart failure(74) , and it is obvious that
the use of a potentially toxic drug might further
complicate this critical state .

The second is severe

renal damage , which has been commonly associated with
cases of extreme toxicity due apparently to deficient
excretion . (21 74 88)

However, mild renal impairment

is not incompatible with use of the thiocyanates .
To summarize these conflicting opinions we may
state that the thiocyanates ~are most effective in
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treating essential hypertension , but that they are of
distinct benefit in many cases complicated by arteriosclerosis , old age , and mild renal involvement .
Definite contraindications consist of severe cardiac
and renal damage and , of course , the appearance of
severe toxicity described below .
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TOXICITY

The toxic manifestations of the thiocyanates vrere
noted by Pauli in his early employment of the dru~,
and practically every report since that time mentions
the appearance of untoward symptoms.

Pau.11(79) ob-

served two cases of rhinitis and the development of
nodular acne similar to that producec by bromide
therapy.

Westphal(lOO) reported several instances

of toxic symptoms, among them weakness and fatigue,
acne, angina, and delerium.

He discovered that by

decreasing the dosage of the drug the frecu.ency of
their occurrence was reduced.
In 1925 Nichols

published a sunnnary of the toxic

reactions· in laboratory animals , defined the lethal
dose of several species, and reviewed three suicidal
deaths attributed to the drug.(75)

As the thiocyanates

gained in popularity, the growing list of reports describing toxic effects soon demonstrated its danger.
In 1931 Healy{56) reported the deaths of two patients
who were receiving supposedly therapeutic doses, and
the next year Goldring and Chasis(48) revealed two
more fatal cases under the same circumstances.

Severe

intoxications were wide spread, and a few descriptions
of the development of exfoliative dermatitis appeared.
These observers were unable to correlate the occurrence
of toxic symptoms with total dosage.

Therefore, interest
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in the thiocyanates lagged until 1936 when Barker perfected a method of determining blood levels of the
drug . (10)

He stated that there was a definite cor-

relation between blood levels and toxicity, and reports
since that time have generqlly supported this claim.
The symptoms of thiocyanate toxicity are multiple,
and due to overlapping betv,e en these and the symptoms
accompaning hypertension itself , considerable confusion may be encountered in their evaluation .

It is

vital for the practitioner to recop,nize and understand
the manifestations of toxicity if he is to employ the
· drug .
The symptoms may be divided into two groups according to the blood levels at which they occur and
their prognostic ~ignificance . (94 96)
Mild Manifestations :
Symptoms observed at safe blood levels include
weakness and fatigue , aching of muscles , increased
irrit ab ility, mild dermatitis , t hyr oid enlargem0nt ,
pyrosis , abdominal discomfort , anor exia , nausea , and
rarely loss of libido, and rhinorrhea .
Weakness and fatigue ~re seen in 75t of patients
during the early weeks of tre a tment , disappear spontaneously in 2- 6 weeks , and have been attributed
t~ the effects of decreased blood pressure . (96)

The
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mechanism by which aching in the calf of leg is produced is obscure .
The symptom of increased irritability has been
noted by a few observers , but in general the reverse
effect is reported.

No stimulating or sedative effects

are described by Goodma,n . (49)

Mild dermatitis is not

uncommon and in itself is not important , but the development of a severe exfoliative lesion described
below must be considered.
Thyroid-Enlargement of the thyroid gland has attracted a
good deal of interest , and several reports describing
this lesion have been published . (10 12 96 34 35 39 72
80 83 59)

These include about 16 cases in all .

They

have occurred after thiocyanate therapy extending over
a period of many months .

In the majority of these

patients there has been a clinical picture of hypothyroidism--fatigue , cold intolerance , myxedematous
facies, lid lag, loss of libido , in addition to typical laboratory findings .

Cessation of thiocyanates has

been followed by slow regression of signs and symptoms,
and second trials of the drug by a return of the previous syndrome .

Biopsy specimens of the enlarged ~lands

have not revealed uniform patholo~ical changes .

In

general , the reports describe a wildly hyperplastic
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gland , with increased vascularity and in some cases
papillary overgrowth .
The mechanism responsible for thyroid enlargement
has been dis.c ussed by several authors .

In commenting

on a case presented by Fahlund(34) , Rynearson observes
that the cyanide ion is the active principle of many
of the kno,m goitrigenous substances .

A similar cause

has been suggested by Foulger and Rose(39) who point
out the hyperplasia of thyroid tissue which occurs
secondary to intracellular anoxia due to cyanide poisoning .

However , they admit that available evidence

proves that the thiocyanate ion remains intact and
extracellular in the body .

Laboratory experiment~

by Astwood{4) have confirmed the hyperplastic effect
of the drug on the thyroid gland , and this author
attributes the action to direct thyroid inhibition
followed by compensatory hyperplasia.
From the practical standpoint thyroid enlar~ement
alone need not be an indication for cessation of ther apy .

Good results have been obtained by simultaneous

administration of either iodine or thyroid extract . (12
35 72 83 96)
The above symptoms of toxicity are commonly observed
at therapeutic blood levels and in themselves constitute
no contraindication to therapy .

It is vitally impor -

-21 -

tant to distinguish them f'rom the manif'estations occur ring at danger ously elevated levels .

The appearance

of the latter should be followed by immediate cessation
of treatment and high fluid intake in an attempt to
increase renal elimination.
Dangerous Manif es t ations :
.Among the first symptoms noted at elevated blood
levels are persistent nausea and vomiting , and less
often severe diarrhea accompanied by abdominal pain . (96
76 94)

Subsequent manifestations may be classified

as cutaneous , vascular , and cerebral .
Cutaneous-Reports of 7 cases of severe cutaneous reactions
are found in the literature .

These have consisted of

an exf'oliative dermatitis appearing usually between the
10th and 20th days after onset of t reatment , and dis appearing with its cessation.

Logefeil(65) renorted

the first two cases in 1929 , and shortly thereafter
Weis and Ruedmann(98) and Ayman(5) published accounts
of two more reactions .

The following year Tyrrell

presented another case , accompanied by a fever of 103°
and edema of the _lids .

In 1937 Baker and Brunsting(9)

described the development of a severe papulo-urtic ~rial
lesion with conjunctivitis , ,pharyngitis , and fever .
None of these reports were accompanied by blood cyanate
levels .

-22-

Only one case of acute dermatitis has been reported
in which blood levels were determined.

Green and Sno,•,(59)

observed the appearance of a severe pruritic urticarial
rash in a patient with a history of allergy .

It occurred

on the 9th day of treatment after the ingestion of 5.2 gm
of thiocyanates.

Edematous eyelids and conjunctivitis

were noted; nasal and pharyngeal conge stion were prominent, and were _relieved by ephedrine.
in this patient never exceeded 6 mgm%.

Blood levels
Again the lesion

disappe a red in a"bout a week after treatm,,mt stopped
and a generalized exfoliation occurred.
The severe cutaneous lesions appear to be an exception to the observation that serious toxicity does
not occur at low blood levels.

The action of the drug

.

in these cases has been attributed to true idiosyncrasy
and similarity is noted to an allergic response.
Cardio-vascular-Another type of severe intoxication involves vasomotor collapse.(56 94 96)

This is characterized by

excessive fall in blood pressure, weakness, and often
typical anginal at t acks.(12 47 83)

The anginal pains

may be the result of diminished blood pressure and
resultant myocardial anoxia.(78)

The attacks have

been well correlated with thiocyanate medication and
blood pressure fall, and together with signs of
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imminent peripheral failure constitute a well defined

indication f'or removal of the drug.
Cerebral-Cerebral symptoms have been observed very commonly_
in the seriously toxic and moribund patient.(43 48 56
88 96)

Often slurring speech unnoticed by the patient

is the earliest indication of involvement.

This is fol-

lowed by visual and auditory hallucinations, delusions,
confusion, delerium, convulsions, coma and finally
death.

The freauency with which these have been noted

in fatal and near-fatal cases necessitates prompt removal of the drug.

In two of these cases symptoms

began at only slightly elevated blood levels, and delay in stopping the drug resulted in fatal outcome.
Therefore, even minor elevation in blood levels when
accompanied by cerebral manifestations must be recognized as a contraindication of paramount importance.
Fatal Cases:
Nine cases of deaths resulting from thiocyanates
have been reported.

In the first three the drug was

taken apparently with suicidal intent.

The dose was

not known accurately in these cases , and observation
was necessarily limited.(88)
The remaining 6 deaths resulted from the use of
the drug in the treatment of hypertension, 4 being
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reported before blood level determinations were available(48 56) and 2 after this time . (43 88)

The signs

and symptoms which preceded death included nausea and
vomiting , rarely those of vasomotor collapse , and usua lly the evidences of cerebral psychosis enum~rated
above .
The dose of thiocyanates given in the 6 treated
cases varied between 5 . 6 and 14 . 5 gm, and death
occurred between the 10th and 18th days .

The amount

of the drug taken cannot be c_o nsidered as excessive .
Blood levels obtained in the last 2 cases vrere in the
critical zone of 15-20 mgm which is above that recommended as safe.

However , Barker has reported cases in

which serious manifestations were not noted until levels of 30-50 mgm were reached . (96)
It seems obvious therefore that certain rare oases
reacting acutely to comparatively low dosage and blood
levels must be £xplained on the basis of idiosyncrasy .
This theory has been advanced by Russell and Garvin in
their reports of fatal cases.(43 88)

In absence of

other evidence the bl . od levels betv,een 15-20 mgm in
these rare patients should be considered critical .
In view of the brief period elapsing between onset of
therapy and the appearance of toxic symptoms , it is
especially importan~ that the patient be followed carefully during the first 3 weeks .
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MODE OF ACTIOW

The method by which the thiocyanates produce a
hypotensive effect is hardly better understood today
than it was a century ago when Claude Bern~rd reported
on their pharmacologic actions.

Indeed, some experi-

mental evidence fails to demonstr a te any suqh effect
in laboratory anin1als. ( 55)

This f a ilure has been one

of the major points of criticism a gainst thiocyana te
therB.py.

Other workers have found definite hypoten-

sive a ction, how3ver, and the discrepancy has not b Aen
reconciled to date.
The theories concerning the mode of action of the
thiocyanates have been classified as vasomotor, card iac,
hematic, sedative, and metabolic.
Vasomotor-Bernard proved that the drug exerted a d irect
toxic effect on skeletal muscle fibers, and this has
-

been postulated as a likely mode of a ction affecting
the smooth muscles of the art e rioles.(49)

Experiments

performed b y Griffith suppor t this t h eory indirectly,
but -obs ervation of animal tissue perfusions ha s failed
to demonstra t e actual va so-dilatation.(38 60 86}

Da vis

and Ba rker(29) noted a prompt fall of pressure in a
limited numb e r of dogs studied in acute and long r an ge
experiments.

They observed a definite increase in
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coronary blood .flow and assumed that a concomitant

generalized vasodilatation produeed the hypotensi-ve
effect.

Another theor-y: of' decreased arteriolar tonus was

advanced by Westphal. {100)

He suggested that .the thio,...

cyanates increase permeability o:f the cell :m,embrane o:f
smooth muscles allowing increased escape of a vaso
spastic substance(which he considered to be choles

terol) and consequent relaxation of arteriolar museies.
Indirect support has been furnished by Gellhorn{44 45)
who has discovered that the thiocyanate anion does
increase pe�eability of the cell membrane Qf striated

muscle-.

Actual escape of vasospastic substance and

resultant vasodilatation are as yet unproved.

Pau1i(79) reported that ·the- drug exhibited a maxl'
mum. inhibiting ef.feet on precipitntion o.f protein on
the inti.ma, and suggested t hat sclerotic chang�s were

ther-eby prevented. Another early observer(62) theor
ized that the !lypotensive ef.fect resulted �rom a

solvent action of the thioeyanates on the ca1careous

deposits of arteriosc�erotic vessel wal1s, but this
elaim has been refuted.(15)
Cardiae--

Bernard(l4) noted that the heart was depressed

and cardiac arrest occurred 1n diastole when he
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injected �hiocyanate into eJ:(perimental. animals.

Nichols

reported depression of the normal heart, but did not
attempt to explain the mechanism.

In trying to account

for this supposed cardiac d.epression, Takacs(9·3) pro
posed that it resulted from vagal stimulation.

There

has been no confirmation of this theory.
Hemat1c--

Doles(31 32) has attempted to prove that a definite

group of hype-rtension is caused by macroeytosis, and he
has obs�rved a correlation between blood pressure re

duction and decrease in red cell size.

Other aut.hors

have reported no significant cpang�s in the erytliro
eytes during therapy.(68)

---Sedative-Paul1(79) credited the drug with a sedative effect,

and Smith{9J.) classed it as a mild hypnotic and sedative.
However, Nichols(75) and Fineberg(36} were una�le to
verify this finding, and Goodman and Gilman(49) do not
mention any action on the.central nervous system.
Metabol1c-�ore recently Friend and Robinson(41) determined
the oxygen consumption of tissue perfused for a short
period in a solution of thiocyanate.

In high concen

trations the metabqlic rate is definitely diminished,
but the lowest level at which a de-f'in1te decrease
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occurred ranged between 20-30 mgm..%, above the norma1
therapeutic 1evels.

The �ffect of more prolo�ged ex

posure at these lower levels remains to be determined.
The finding of lowered oxygen consumption can be cor
related with those not uncommon patients on a thiocy
anate regime-who exhibit a definite clini�al picture
of hypothyroidism.(39 72 85)

However, the majority

of cases exhibit none of the signs or symptoms ot
myxedema.

From this variety of con:flicting evidence and

theories we can conclu�e on17 that the mode of action
of the thiooyanates remains undetermined.
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CONCLUSIONS
1. The majority of clinical observers credit the thio
cyanates with a definite hypotensive effect in cases of
essential hypertension.

This effect has not been dem

onstrated conclusively in experimental animals.
2. The thioeyanates give definite and oecas1ona1ly
striking symptomatic relief.
3. No increased longevity has been proved in patients
receiving thiocyanate therapy.

Such a proof would

constitute ·an important justification for their.use.
4. Contraindications to treatment consist of marked

renal impairment and cardiac damage.

5. A classification of the toxic manifestations has

been presented.

Many of these are mild; a few are

serious and require prompt cessation of trea.tment.
6. Management is guided by clinical observation and
by a careful reguiation of blood levels, whieh should
not exceed the 8-12 mgm therapeutic rahge.

The mar

gin between this therapeutic level and that where•

toxic ·symptoms appear is fa1r1y wide :in most _patients.

However, rarely patients exhibit a sensitivity to the
drug and develop exceed1l_lgly serious reaetions.
reactions occur within the first 3 weeks

These

or treatment,

s-o careful supervision is vital during this period •

6. The mode of action by whieh the thiocyanates produce a hypotensive effect is unknown.
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